Cart
sales@molnova.com
GSK-2881078
CAS No. 1539314-06-1
GSK-2881078 ( GSK2881078;GSK 2881078 )
Catalog No. M12175 CAS No. 1539314-06-1
A potent and selective androgen receptor modulator (SARM) for the treatment of cachexia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 58 | In Stock |
|
| 10MG | 87 | In Stock |
|
| 25MG | 192 | In Stock |
|
| 50MG | 312 | In Stock |
|
| 100MG | 520 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-2881078
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective androgen receptor modulator (SARM) for the treatment of cachexia.
-
DescriptionA potent and selective androgen receptor modulator (SARM) for the treatment of cachexia.Other Indication Phase 1 Clinical
-
SynonymsGSK2881078;GSK 2881078
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogenReceptor
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1539314-06-1
-
Formula Weight330.33
-
Molecular FormulaC14H13F3N2O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 33 mg/mL
-
SMILESN#CC1=C(C(F)(F)F)C2=C(N([C@H](C)CS(=O)(C)=O)CC2)C=C1
-
Chemical Name1H-Indole-5-carbonitrile, 1-[(1R)-1-methyl-2-(methylsulfonyl)ethyl]-4-(trifluoromethyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Trenbolone acetate
Trenbolone acetate (RU-1697,17beta-TBOH) is a potent testosterone analog and selective androgen receptor modulator.
-
GLPG-0492
A novel, orally active, non-steroidal selective androgen receptor modulator (SARM) with in vitro potency of 13 nM.
-
UT-34
UT-34 is a selective and orally active antagonist of second-generation pan-androgen receptor (AR) and degrader(IC50s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively), and has anti-prostate cancer efficacy. In LNCaP cells, UT-34 (3-10 μM; 24 hours) treatment inhibits the expression of PSA and FKBP5 and growth of LNCaP cells starting from 100 nM with maximum effect observed at 10 μM.
